JAK-2

Isoforms Recommended:	JAK2

By Targets:	JAK (143) Apoptosis (28) Arginase (1) Aurora Kinase (3) Autophagy (11) Bacterial (1) Bcr-Abl (3) Biochemical Assay Reagents (1) Btk (2) CDK (6) COX (3) Deubiquitinase (2) EGFR (3) Endogenous Metabolite (2) ERK (1) FGFR (1) FLT3 (15) GSK-3 (4) HDAC (2) Interleukin Related (4) Isotope-Labeled Compounds (2) LRRK2 (1) MEK (2) Microtubule/Tubulin (1) nAChR (1) NF-κB (2) NO Synthase (2) Orthopoxvirus (1) p38 MAPK (2) Parasite (1) PI3K (1) PKC (1) Polo-like Kinase (PLK) (2) PROTACs (5) Reactive Oxygen Species (1) RET (3) Small Interfering RNA (siRNA) (3) Src (1) STAT (19) Syk (6) TGF-β Receptor (2) TNF Receptor (1) Toll-like Receptor (TLR) (1) Trk Receptor (1) VEGFR (2) Virus Protease (1)
By Research Areas:	Cancer (106) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (56) Metabolic Disease (4)

Targets Recommended: JAK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-102055

JAK2 JH2 Tracer

4 Publications Verification

JAK Others

JAK2 JH2 Tracer (Tracer 5) is a fluorescent probe for JAK2 JH2 domain, with a K_d of value 0.2 μM ^[2].

JAK2 JH2 Tracer 4 Publications Verification	JAK	Others
JAK2 JH2 Tracer (Tracer 5) is a fluorescent probe for **JAK2 JH2 domain, with a K_d** of value 0.2 μM ^[2].

HY-146186

JAK2 JH2 binder-1	JAK	Cancer
JAK2 JH2 binder-1 (compound 11) is a potent and selective **JAK2 JH2 binder, with a K_d** of 37.1 nM. JAK2 JH2 binder-1 has the potential for various myeloproliferative neoplasms research .

HY-15480

NSC 42834 1 Publications Verification JAK2 Inhibitor V; Z3	JAK	Cancer
NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of *Jak2, inhibits Jak2-V617F and Jak2*-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.

HY-RS07018

JAK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
JAK2 Human Pre-designed siRNA Set A contains three designed siRNAs for JAK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

JAK2 Human Pre-designed siRNA Set A JAK2 Human Pre-designed siRNA Set A

HY-RS07019

Jak2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Jak2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Jak2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Jak2 Mouse Pre-designed siRNA Set A Jak2 Mouse Pre-designed siRNA Set A

HY-RS07020

Jak2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Jak2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Jak2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Jak2 Rat Pre-designed siRNA Set A Jak2 Rat Pre-designed siRNA Set A

HY-10652

JAK-2/3-IN-1	JAK	Inflammation/Immunology Cancer
JAK-2/3-IN-1 is a potent *JAK-2* and *JAK-3* inhibitor extracted from patent US8163732B2, compound 46, has K_is of <250 nM for both isoforms .

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective *JAK2* inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) .

HY-137756

JAK2-IN-6	JAK	Cancer
JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective *JAK2* inhibitor with an IC₅₀ of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells .

HY-100759

JAK2-IN-4

JAK Cancer

JAK2-IN-4 (compound 16h) is a selective JAK2/JAK3 inhibitor, with IC₅₀ values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively .

JAK2-IN-4	JAK	Cancer
JAK2-IN-4 (compound 16h) is a selective *JAK2/JAK3* inhibitor, with IC₅₀ values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively .

HY-131906

JAK2-IN-7	JAK FLT3 Apoptosis	Cancer
JAK2-IN-7 is a selective *JAK2* inhibitor with IC₅₀s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3 ^V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities .

HY-130247

JAK2/FLT3-IN-1 1 Publications Verification	JAK FLT3 Apoptosis	Cancer
JAK2/FLT3-IN-1 is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity .

HY-143884

JAK2/TYK2-IN-1	JAK	Inflammation/Immunology
JAK2/TYK2-IN-2 is a potent and selective *TYK2* inhibitor with IC₅₀ values of 9 and 157 nM for *TYK2* and *JAK2, respectively. JAK2*/TYK2-IN-2 has anti-inflammatory activity .

HY-130247A

JAK2/FLT3-IN-1 TFA 1 Publications Verification	JAK FLT3 Apoptosis	Cancer
JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity .

HY-151285

JAK-2/3-IN-3	Apoptosis JAK	Inflammation/Immunology Cancer
JAK-2-/3-IN-3 (compound ST4j) is a potent *JAK2/3* inhibitor with IC₅₀s of 13.00 and 14.86 nM for *JAK2* and *JAK3, respectively. JAK-2-/3-IN-3 inhibits autophosphorylation of JAK2* and induces apoptosis in a dose- and time-dependent manner. JAK-2-/3-IN-3 can be used in studies of lymph derived diseases and leukemia .

HY-131194

JAK2/STAT3-IN-1

Interleukin Related Cancer

JAK2/STAT3-IN-1 (compound (S)-10a) is a potent GP130 inhibitor with an IC₅₀ of 3.04 µM. JAK2/STAT3-IN-1 shows anti-tumor activity .
HY-151256

JAK-2/3-IN-2

JAK Cancer

JAK-2/3-IN-2 (Compound 3h) is a JAK2 and JAK3 inhibitor with IC₅₀s of 23.85 nM and 18.9 nM, respectively .

JAK2/STAT3-IN-1	Interleukin Related	Cancer
JAK2/STAT3-IN-1 (compound (S)-10a) is a potent GP130 inhibitor with an IC₅₀ of 3.04 µM. JAK2/STAT3-IN-1 shows anti-tumor activity .

JAK-2/3-IN-2	JAK	Cancer
JAK-2/3-IN-2 (Compound 3h) is a *JAK2* and *JAK3* inhibitor with IC₅₀s of 23.85 nM and 18.9 nM, respectively .

HY-P1590

*Tyrosine Protein Kinase JAK 2* (Phospho-Tyr8, 9)**	JAK	Inflammation/Immunology Cancer
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

HY-156423

*Tubulin/JAK2-IN-1*	Microtubule/Tubulin JAK	Cancer
Tubulin/JAK2-IN-1 (compound 7g) is a dual inhibitor of Janus kinase 2 (JAK2) and microtubule. Tubulin/JAK2-IN-1 has potent antiproliferative activity against the cancer cells .

HY-146066

*α7 nAchR-JAK2-STAT3 agonist 1*	nAChR JAK STAT NO Synthase	Inflammation/Immunology
α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC₅₀ value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .

HY-145696

SJ10542	PROTACs JAK	Inflammation/Immunology Cancer
SJ10542 is a potent and selective *JAK2/3* directing phenyl glutarimide (PG)-PROTAC with DC₅₀s of 14, 11, and 24 nM for JAK2, JAK3, and JAK2-fusion ALL, respectively. SJ10542 utilizes a PG ligand as the cereblon (CRBN) recruiter .

HY-18960

CHZ868

5 Publications Verification

JAK Cancer

CHZ868 is a type II JAK2 inhibitor with an IC₅₀ of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.

CHZ868 5 Publications Verification	JAK	Cancer
CHZ868 is a type II *JAK2* inhibitor with an IC₅₀ of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.

HY-113573

Protosappanin A PTA	JAK STAT	Inflammation/Immunology
Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses *JAK2/STAT3*-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3 .

HY-112391

SD-1029	JAK STAT	Cancer
SD-1029 is a *JAK2/STAT3* inhibitor . SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation ^[2].

HY-13775

XL019 4 Publications Verification	JAK Apoptosis	Cancer
XL019 is a potent, orally active, and selective *JAK2* inhibitor, with IC₅₀s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2 ^[2].

HY-124858

SC99	STAT JAK Apoptosis	Cardiovascular Disease Cancer
SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities ^[2] .

HY-115452

G5-7	JAK Apoptosis	Cancer
G5-7, an orally active and allosteric *JAK2* inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr ¹⁰⁶⁸) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study .

HY-N1405

Cucurbitacin I 5+ Cited Publications Elatericin B; JSI-124; NSC-521777	STAT JAK	Cancer
Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-10410

TG101209 4 Publications Verification	FLT3 JAK RET Autophagy Apoptosis	Cancer
TG101209 is a selective *JAK2* inhibitor with IC₅₀ of 6 nM, less potent to Flt3 and RET with IC₅₀ of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.

HY-N1356

Reticuline	JAK STAT NF-κB Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology
Reticuline shows anti-inflammatory effects through *JAK2/STAT3* and NF-κB signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3 . Reticuline exhibits cardiovascular effects ^[2].

HY-153568

JAK1-IN-11	JAK	Cancer
JAK1-IN-11 (compound 11) is a potent inhibitor of JAK，with IC₅₀s of 0.02 nM (JAK1)，and 0.44 nM (JAK2)，respectively. JAK1-IN-11 has high selectivity against JAK1 over JAK2 .

HY-147330

SJ1008030	PROTACs JAK	Cancer
SJ1008030 (compound 8) is a JAK2 PROTAC which selectively degrades *JAK2. SJ1008030 inhibits MHH–CALL-4 cell growth with an IC₅₀* of 5.4 nM. SJ1008030 can be used for the research of leukemia .

HY-10411

AZ960

JAK Apoptosis Parasite Virus Protease Cancer

AZ960 is a potent and specific inhibitor of the JAK2 kinase with a K_i of 0.45 nM.
HY-107594

Benzene hexabromide

JAK Cancer

Benzene hexabromide, a bromohydrocarbon, is a potent inhibitor of JAK2 tyrosine kinase autophosphorylation.

AZ960	JAK Apoptosis Parasite Virus Protease	Cancer
AZ960 is a potent and specific inhibitor of the *JAK2* kinase with a K_i of 0.45 nM.

Benzene hexabromide	JAK	Cancer
Benzene hexabromide, a bromohydrocarbon, is a potent inhibitor of *JAK2* tyrosine kinase autophosphorylation.

HY-147330A

SJ1008030 TFA	PROTACs JAK	Cancer
SJ1008030 (compound 8) TFA is a JAK2 PROTAC which selectively degrades *JAK2. SJ1008030 TFA inhibits MHH–CALL-4 cell growth with an IC₅₀* of 5.4 nM. SJ1008030 TFA can be used for the research of leukemia .

HY-147330B

SJ1008030 formic	PROTACs JAK	Cancer
SJ1008030 (compound 8) formic is a JAK2 PROTAC which selectively degrades *JAK2. SJ1008030 formic inhibits MHH–CALL-4 cell growth with an IC₅₀* of 5.4 nM. SJ1008030 formic can be used for the research of leukemia .

HY-19631A

Ilginatinib NS-018	JAK	Cancer
Ilginatinib (NS-018) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-19631B

Ilginatinib hydrochloride NS-018 hydrochloride	JAK	Cancer
Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-19631

Ilginatinib maleate NS-018 maleate	JAK	Cancer
Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable *JAK2* inhibitor, with an IC₅₀ of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC₅₀, 33 nM), JAK3 (IC₅₀, 39 nM), and Tyk2 (IC₅₀, 22 nM).

HY-15315A

Baricitinib phosphate 35+ Cited Publications LY3009104 phosphate; INCB028050 phosphate	JAK	Inflammation/Immunology
Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable *JAK1/JAK2* inhibitor with IC₅₀ of 5.9 nM and 5.7 nM, respectively.

HY-18293

NSC 33994

JAK Autophagy Cancer

NSC 33994 (G6) is a selective JAK2 inhibitor, with an IC₅₀ of 60 nM .

NSC 33994	JAK Autophagy	Cancer
NSC 33994 (G6) is a selective *JAK2* inhibitor, with an IC₅₀ of 60 nM .

HY-10409

Fedratinib 30+ Cited Publications TG-101348; SAR 302503	JAK Apoptosis	Cancer
Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research ^[2].

HY-10409A

Fedratinib hydrochloride hydrate 30+ Cited Publications TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate	JAK Apoptosis	Cancer
Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research ^[2].

HY-109179A

Itacnosertib (hydrocholide)

TP-0184 (hydrocholide)
JAK TGF-β Receptor Cancer

Itacnosertib hydrocholide is an inhibitor of JAK2, ACVR1 (ALK2) and ALK5 .

Itacnosertib (hydrocholide) TP-0184 (hydrocholide)	JAK TGF-β Receptor	Cancer
Itacnosertib hydrocholide is an inhibitor of *JAK2, ACVR1 (ALK2)* and ALK5 .

HY-N0635

Prim-O-glucosylcimifugin 2 Publications Verification	NO Synthase COX	Inflammation/Immunology
Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and *COX-2* expression by through regulating JAK2/STAT3 signaling.

HY-15166B

(E/Z)-Zotiraciclib citrate

(E/Z)-TG02 citrate; (E/Z)-SB1317 citrate
CDK JAK FLT3 Cancer

(E/Z)-Zotiraciclib citrate is a potent CDK2, JAK2, and FLT3 inhibitor .
HY-149647

HD-2a

Others Inflammation/Immunology

HA-2a can inhibit the JAK2/STAT3 pathway via downregulates circDcbld2 expression in RAW264.7 cells .

(E/Z)-Zotiraciclib citrate (E/Z)-TG02 citrate; (E/Z)-SB1317 citrate	CDK JAK FLT3	Cancer
(E/Z)-Zotiraciclib citrate is a potent *CDK2, JAK2, and FLT3* inhibitor .

HY-14722A

NVP-BSK805 dihydrochloride 1 Publications Verification	JAK	Cancer
NVP-BSK805 dihydrochloride is an ATP-competitive *JAK2* inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

HY-N1535

Ponicidin 2 Publications Verification Rubescensine B
Ponicidin (Rubescensine B) is a diterpenoid derived from Rabdosia rubescens, and exhibits immunoregulatory, anti-inflammatory, anti-viral and anti-cancer activity. Ponicidin (Rubescensine B) induces apoptosis of gastric carcinoma cell, decreases the phosphorylation of JAK2 and STAT3, and shows no effect on protein levels of JAK2 and STAT3 .

HY-14722C

NVP-BSK805 trihydrochloride	JAK	Cancer
NVP-BSK805 trihydrochloride trihydrochloride is an ATP-competitive *JAK2* inhibitor, with IC₅₀s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library

419 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 419 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Cat. No.	Product Name	Type

HY-102055

JAK2 JH2 Tracer

4 Publications Verification

Fluorescent Dyes/Probes

JAK2 JH2 Tracer (Tracer 5) is a fluorescent probe for JAK2 JH2 domain, with a K_d of value 0.2 μM ^[2].

Cat. No.	Product Name	Type

HY-110002

LFM-A13	Biochemical Assay Reagents
LFM-A13 is a potent BTK, *JAK2, PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research

HY-W127408

Tripalmitolein

Biochemical Assay Reagents

1,2,3-Tripalmitoleoyl-rac-glycerol is a triacylglycerol containing palmitoleic acid at the sn-1, sn-2 and sn-3 positions. It reduces erythrocyte deformability in a concentration-dependent manner in the Reid filtration assay. Hepatic levels of 1,2,3-tripalmitoleoyl-rac-glycerol are increased in a JAK2L mouse model of hepatic steatosis. 1,2,3-Tripalmitoleoyl-rac-glycerol plasma levels are reduced in patients with predialysis renal disease.

Cat. No.	Product Name	Target	Research Area

HY-143884

JAK2/TYK2-IN-1	JAK	Inflammation/Immunology
JAK2/TYK2-IN-2 is a potent and selective *TYK2* inhibitor with IC₅₀ values of 9 and 157 nM for *TYK2* and *JAK2, respectively. JAK2*/TYK2-IN-2 has anti-inflammatory activity .

HY-P1590

*Tyrosine Protein Kinase JAK 2* (Phospho-Tyr8, 9)**	JAK	Inflammation/Immunology Cancer
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

HY-P1790

Axltide

JAK Metabolic Disease

Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases .

HY-P10114

STAT3-IN-24, cell-permeable PpYLKTK-mts; STAT3 PI	STAT	Cancer
STAT3-IN-24, cell-permeable (PpYLKTK-mts) is a STAT3 peptide inhibitor. STAT3-IN-24, cell-permeable inhibits recruitment of STAT3 to Jak2 and phosphorylation of Y705, thus preventing the dimerization and the nuclear translocation of STAT3 .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113573

Protosappanin A PTA	Structural Classification Classification of Application Fields Leguminosae Caesalpinia sappan L. Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields	JAK STAT
Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses *JAK2/STAT3*-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3 .

HY-N1405

Cucurbitacin I Maximum Cited Publications 10 Publications Verification Elatericin B; JSI-124; NSC-521777	Triterpenes Structural Classification Classification of Application Fields Terpenoids Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Cancer	STAT JAK
Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-N1356

Reticuline	Cardiovascular Disease Alkaloids Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Plants Lauraceae Isoquinoline Alkaloids Disease Research Fields Lindera aggregata (Sims) Kosterm.	JAK STAT NF-κB Endogenous Metabolite
Reticuline shows anti-inflammatory effects through *JAK2/STAT3* and NF-κB signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3 . Reticuline exhibits cardiovascular effects ^[2].

HY-N0635

Prim-O-glucosylcimifugin 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Ophryosporus axilliflorus Hieron. Source classification Plants Umbelliferae Inflammation/Immunology Disease Research Fields	NO Synthase COX
Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and *COX-2* expression by through regulating JAK2/STAT3 signaling.

HY-N1405R

Cucurbitacin I (Standard) Elatericin B (Standard); JSI-124 (Standard); NSC-521777 (Standard)	Structural Classification Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Cancer	STAT JAK
Cucurbitacin I (Standard) is the analytical standard of Cucurbitacin I. This product is intended for research and analytical applications. Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity ^[2].

HY-121471

Chrysoeriol 1 Publications Verification	Structural Classification Classification of Application Fields Flavones Metabolic Disease Plants Phyllanthus Flavonoids Phenols Polyphenols Euphorbiaceae Brassicaceae Disease Research Fields Coronopus didymus	Endogenous Metabolite
Chrysoeriol is a kind of natural yellow ash, which can be used for heating plants Coronopus didymus. Chrysoeriol suppresses the JAK2/STAT3, IκB/p65, and NF-κB pathways, and has strong anti-inflammatory activity.

HY-N2963

Broussonin E	Structural Classification Thymelaeaceae Source classification Daphne giraldii Nitsche Phenols Polyphenols Plants	ERK p38 MAPK JAK STAT TNF Receptor Interleukin Related COX Arginase
Broussonin E is a phenolic compound and shows anti-inflammatory activity. Broussonin E can suppress inflammation by modulating macrophages activation statevia inhibiting the ERK and p38 MAPK and enhancing *JAK2-STAT3* signaling pathway. Broussonin E can be used for the research of inflammation-related diseases such as atherosclerosis .

HY-N7452

Coumermycin A1	Structural Classification Microorganisms Antibiotics Source classification	JAK Bacterial Orthopoxvirus
Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria. Coumermycin A1 shows anti-orthopoxvirus activity.

HY-N0678

Icaritin 1 Publications Verification Anhydroicaritin	Flavonols Structural Classification Classification of Application Fields Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Phenols Polyphenols Epimedium brevicornu Maxim. Berberidaceae Disease Research Fields Cancer	Autophagy Apoptosis
Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 µM) and primary CML cells (IC₅₀ of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis ^[2] ^[3.

HY-N1356A

(R)-Reticuline	Structural Classification Alkaloids Source classification Plants Lauraceae Isoquinoline Alkaloids Lindera aggregata (Sims) Kosterm.	Others
(R)-Reticuline is an isomer of Reticuline (HY-N1356). Reticuline displays anti-inflammatory and cardiovascular effects through JAK2/STAT3 and NF-κB signaling pathways. Salutaridine is a key intermediate in morphine biosynthesis. Salutaridine can be converted from (R)-Reticuline in the poppy plant. The conversion system relies on membrane-bound cytochrome P-450 enzymes and also requires reducing cofactors NADPH, molecular oxygen, etc ^[2].

HY-N0201

Atractylenolide I 2 Publications Verification	Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Source classification Astragalus caprinus L. Plants Compositae Disease Research Fields Cancer	Toll-like Receptor (TLR) JAK STAT
Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated *JAK2* and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

HY-N2515

Ginsenoside Rk1 2 Publications Verification	Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields Araliaceae	NF-κB PI3K JAK Apoptosis
Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures . Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of *Jak2/Stat3* signaling pathway and NF-κB ^[2]. Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis . Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .

Recombinant Proteins Recommended:

JAK2

Species:	Human (3)
Tag:	His (2) Tag Free (1)
Source:	Sf9 insect cells (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P701102

	*Janus kinase 2/JAK2* Protein, Human (381aa, His)** JAK 2; JAK-2; JAK2; JAK2_HUMAN; Janus Activating Kinase 2; Janus kinase 2 (a protein tyrosine kinase); Janus kinase 2; JTK 10; JTK10; kinase JAK2; OTTHUMP00000043260; THCYT3; Tyrosine protein kinase JAK2; Tyrosine-protein kinase JAK2	Human	E. coli
	Janus kinase 2/JAK2 Protein, Human is a recombinant human JAK2 expressed in E. coli with a His tag at the N-terminus. JAK2 is a non-receptor tyrosine kinase.

HY-P702720

Janus kinase 2/JAK2 Protein, Human (sf9)

JAK2; Janus kinase 2; tyrosine-protein kinase JAK2; JTK10; JAK-2; Janus kinase 2 (a protein tyrosine kinase); THCYT3
Human Sf9 insect cells

HY-P7989

	*Janus kinase 2/JAK2* Protein, Human (His)** JAK2, Janus kinase 2	Human	E. coli
	Janus kinase 2/JAK2 Protein, Human (His) is a recombinant human JAK2 expressed in E. coli with a His tag at the N-terminus. JAK2 is a non-receptor tyrosine kinase.

Cat. No.	Product Name	Chemical Structure

HY-50856S

Deuruxolitinib
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), modulates the activity of *JAK1/JAK2*. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I) .

HY-W062703S

(Rac)-Ruxolitinib-d9

(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor .

HY-15315S

Baricitinib-d5
Baricitinib-d₅ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-15315S1

Baricitinib-d3
Baricitinib-d₃ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-18300S

Filgotinib-d4
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC50 and Ki.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model[1].

HY-W727879

Upadacitinib-15N,d2

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research ^[2].

Cat. No.	Product Name	Application	Reactivity

HY-P80829

*Phospho-JAK2* (Tyr1007/1008) Antibody** JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
Phospho-JAK2 (Tyr1007/1008) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 131 kDa, targeting to Phospho-JAK2 (Tyr1007/1008). It can be used for WB,IHC-P,ICC/IF,IP,FC assays with tag free, in the background of Human, Mouse, Rat.

HY-P80727

JAK2 Antibody (YA330) JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB	Human, Mouse
JAK2 Antibody (YA330) is a non-conjugated and Rabbit origined monoclonal antibody about 131 kDa, targeting to JAK2. It can be used for WB assays with tag free, in the background of Human, Mouse.

HY-P80421

JAK2 Antibody (YA721)	WB, ICC, IHC-P, FC	Human, Mouse, Rat
JAK2 Antibody (YA721) is a non-conjugated and Mouse origined monoclonal antibody about ~130kDa, targeting to JAK2. It can be used for WB,ICC,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.

HY-P80467

*Phospho-JAK2* (Tyr1007+Tyr1008) Antibody**	WB, ICC, IHC-P, IP	Human, Mouse, Rat
Phospho-JAK2 (Tyr1007+Tyr1008) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 131 kDa, targeting to Phospho-JAK2(Y1007+Y1008). It can be used for WB,ICC,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

JAK-2

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products